Efficacy of Lenvatinib as Subsequent Therapy After Combination Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma.
Durvalumab plus tremelimumab (DT) therapy has demonstrated overall survival benefit in a clinical trial and is now widely used as first-line treatment for unresectable hepatocellular carcinoma (u-HCC). However, evidence supporting the efficacy of lenvatinib (LEN) as subsequent therapy after DT progression remains limited.
This multicenter study enrolled patients who received LEN as first-line therapy (1st-line LEN) and those who received LEN as second-line therapy following DT treatment (2nd-line LEN following DT). The primary endpoints were disease control rate (DCR) and objective response rate (ORR), which were compared between the 1st-line LEN and 2nd-line LEN following DT. Treatment responses were assessed using mRECIST.
In the intention-to-treat analysis, DCR was 69.1% in the 1st-line LEN group and 69.2% in the 2nd-line LEN following DT group (p=0.95); ORR was 38.2% and 30.8%, respectively (p=0.44). No significant differences were observed between the two groups. After adjusting for age, sex, and ALBI score, treatment line was not associated with DCR; the odds ratio for 2nd-line LEN following DT versus 1st-line LEN (reference) was 0.83 (95% confidence interval=0.17-4.13, p=0.816).
LEN following DT therapy demonstrated equivalent antitumor efficacy to first-line LEN, supporting LEN as a viable second-line option after DT progression in u-HCC.
This multicenter study enrolled patients who received LEN as first-line therapy (1st-line LEN) and those who received LEN as second-line therapy following DT treatment (2nd-line LEN following DT). The primary endpoints were disease control rate (DCR) and objective response rate (ORR), which were compared between the 1st-line LEN and 2nd-line LEN following DT. Treatment responses were assessed using mRECIST.
In the intention-to-treat analysis, DCR was 69.1% in the 1st-line LEN group and 69.2% in the 2nd-line LEN following DT group (p=0.95); ORR was 38.2% and 30.8%, respectively (p=0.44). No significant differences were observed between the two groups. After adjusting for age, sex, and ALBI score, treatment line was not associated with DCR; the odds ratio for 2nd-line LEN following DT versus 1st-line LEN (reference) was 0.83 (95% confidence interval=0.17-4.13, p=0.816).
LEN following DT therapy demonstrated equivalent antitumor efficacy to first-line LEN, supporting LEN as a viable second-line option after DT progression in u-HCC.
Authors
Uchihara Uchihara, Tamaki Tamaki, Marusawa Marusawa, Urawa Urawa, Hasebe Hasebe, Arai Arai, Ochi Ochi, Kondo Kondo, Mori Mori, Tsuji Tsuji, Fujii Fujii, Ogawa Ogawa, Uchida Uchida, Mori Mori, Toshimori Toshimori, Okamoto Okamoto, Shigeno Shigeno, Akahane Akahane, Narita Narita, Yoshida Yoshida, Yokohama Yokohama, Kubotsu Kubotsu, Yasuda Yasuda, Tada Tada, Nakamura Nakamura, Tsuchiya Tsuchiya, Yasui Yasui, Izumi Izumi, Kurosaki Kurosaki,
View on Pubmed